Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
23-25 May, 2025
Not Confirmed
Not Confirmed
26-27 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
23-25 May, 2025
Industry Trade Show
Not Confirmed
26-27 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities
17 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/norgine-welcomes-tga-registration-in-australia-of-ifinwil-eflornithine-for-adults-and-children-diagnosed-with-high-risk-neuroblastoma-hrnb1-302430883.html
15 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/norgine-strengthens-rare-disease-portfolio-with-acquisition-of-theravia-302427963.html
24 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/x4-pharmaceuticals-announces-ema-validation-of-marketing-authorization-application-maa-for-mavorixafor---licenced-to-norgine-for-commercialisation-in-europe-302359812.html
13 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/13/3008383/0/en/X4-Pharmaceuticals-and-Norgine-Enter-into-Exclusive-Licensing-Agreement-to-Commercialize-Mavorixafor-in-Europe-Australia-and-New-Zealand.html
06 Jan 2025
// PHARMAREVIEW
https://www.europeanpharmaceuticalreview.com/news/240759/nice-makes-first-of-a-kind-recommendation-for-hearing-loss-drug/
06 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/norgine-submits-marketing-authorisation-application-to-the-european-medicines-agency-for-eflornithine-difluoromethylornithine-dfmo-in-high-risk-neuroblastoma-302343043.html
ABOUT THIS PAGE